Erectile Dysfunction Market Report 2026

Erectile Dysfunction Market Overview

• Erectile Dysfunction market size has reached to $2.68 billion in 2025 • Expected to grow to $4.06 billion in 2030 at a compound annual growth rate (CAGR) of 8.6% • Growth Driver: Rising Prevalence Of Lifestyle-Related Diseases To Propel Growth In The Market • Market Trend: Innovations In Medical Technology And Materials Drive Advancements In Erectile Dysfunction Treatments • North America was the largest region in 2025.

What Is Covered Under Erectile Dysfunction Market?

Erectile dysfunction (ED) refers to the inability to achieve or maintain an erection sufficient for satisfactory sexual performance. It is a common condition that can result from various physical, psychological, or lifestyle factors, affecting men's overall well-being and quality of life. The main types of products for erectile dysfunction are drugs and devices. Drugs are chemical formulations used to treat erectile dysfunction by enhancing blood flow to the penis, allowing men to achieve and maintain an erection. The distribution channels include hospital pharmacies, retail pharmacies, and online channels for end users such as hospitals and clinics, ambulatory surgery centers, pharmacies, and others.

What Is The Erectile Dysfunction Market Growth Forecast?

The erectile dysfunction market size is expected to see strong growth in the next few years. It will grow to $4.06 billion in 2030 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to telehealth growth, non-invasive therapy innovation, regenerative medicine research, stigma reduction awareness, personalized men’s health solutions. Major trends in the forecast period include rising use of oral drug therapies, growing adoption of non-invasive devices, expansion of telemedicine-based consultations, increased awareness of men’s health, emphasis on personalized treatment approaches.

Global Erectile Dysfunction Market Segmentation

1) By Product: Drugs, Devices 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Channels 3) By End User: Hospitals And Clinics, Ambulatory Surgery Centers, Pharmacies, Other End Users Subsegments: 1) By Drugs: Phosphodiesterase Type 5 (PDE5) Inhibitors, Hormone Therapy, Injectable Medications, Topical Medications 2) By Devices: Vacuum Erection Devices (VEDs), Penile Implants, Shockwave Therapy Devices

What Is The Driver Of The Erectile Dysfunction Market?

The rising prevalence of lifestyle-related diseases is expected to drive the erectile dysfunction market. Lifestyle-related diseases are health conditions primarily caused by unhealthy habits, such as poor diet, lack of exercise, smoking, and excessive alcohol consumption. The increase in lifestyle-related diseases is due to rising sedentary behavior, poor dietary habits, stress, and unhealthy habits like smoking and excessive alcohol consumption. Erectile dysfunction (ED) serves as an early warning sign for lifestyle-related diseases, such as cardiovascular conditions and diabetes, highlighting the need for timely medical intervention and healthier lifestyle choices. For instance, in 2024, according to the report published by the World Obesity Federation, a UK-based non-profit organization, by 2035, 79% of adults with overweight and obesity will live in Low- and Middle-Income Countries (LMICs) by 2035. Further, 88% of children with overweight and obesity will be living in LMICs by 2035. Therefore, the rising prevalence of lifestyle-related diseases will propel growth of the erectile dysfunction industry.

Key Players In The Global Erectile Dysfunction Market

Major companies operating in the erectile dysfunction market are Pfizer Inc., Bayer AG, Dong-A Socio Holdings Co. Ltd., Eli Lilly and Company, Viatris Inc., Teva Pharmaceutical Industries Limited, Sandoz International GmbH, Sun Pharmaceutical Industries Limited, Coloplast Corporation, Dr. Reddy's Laboratories Limited, Cipla Limited, Ferring Pharmaceuticals A/S, Endo International plc, Zydus Lifesciences Limited, Lupin Limited, Hims & Hers Health Inc., Cadila Pharmaceuticals Limited, VIVUS Inc., Rigicon Inc., Petros Pharmaceuticals Inc., Futura Medical plc, Apricus Biosciences Inc., Initiator Pharma A/S

Global Erectile Dysfunction Market Trends and Insights

Major companies operating in the erectile dysfunction market are focusing on innovative products, such as over-the-counter (OTC) gel, to provide more accessible and convenient treatment options for individuals experiencing erectile dysfunction, thereby expanding their market reach and addressing unmet patient needs. An over-the-counter (OTC) gel is a topical medication available without a prescription, used for treating various conditions directly applied to the skin. For instance, in September 2024, Haleon plc, a UK-based consumer healthcare company, launched Eroxon, the first FDA-cleared over-the-counter gel for erectile dysfunction (ED). This innovative product offers a non-invasive, fast-acting solution for ED, designed to provide enhanced accessibility and convenience for patients. Its ease of use, offering a topical application that eliminates the need for oral medications, reduces potential systemic side effects.

What Are Latest Mergers And Acquisitions In The Erectile Dysfunction Market?

In July 2023, Futura Medical plc, a UK-based provider of sexual-health products including Eroxon® (MED3000), partnered with Haleon plc to commercialize Eroxon® in the United States. Through this collaboration, Haleon is responsible for the product’s marketing, regulatory approvals, and commercial launch, while Futura provides technical support and ongoing product expertise. This partnership highlights the growing focus on bringing innovative erectile dysfunction therapies to new markets through strategic commercialization collaborations. Haleon plc is a UK-based consumer health company.

Regional Outlook

North America was the largest region in the erectile dysfunction market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Erectile Dysfunction Market?

The erectile dysfunction market consists of sales of medications, devices, and therapies aimed at treating erectile dysfunction. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Erectile Dysfunction Market Report 2026?

The erectile dysfunction market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the erectile dysfunction industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.